People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Reprise Biomedical, Inc. | — | Biotechnology | Series B | $47.1M | $29.7M | 2025 |
Alan Woldt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alan Woldt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Erwin Kelen | 1 | 5 |
| Jeff Ross | 1 | 4 |
| Ronald Eibensteiner | 1 | 4 |
| Tina Walters | 1 | 2 |
| CARRIE POWERS | 1 | 2 |
| Steve Jagodzinski | 1 | 2 |
| Heather Kotila | 1 | 2 |
| Greg Smock | 1 | 2 |
| HOWARD ROOT | 1 | 2 |
| Jake Isenburg | 1 | 2 |
| Tom Kouchoukos | 1 | 2 |
| Jerrod Krueger | 1 | 2 |
| PHIL NALBONE | 1 | 1 |
| Jeff Duncan | 1 | 1 |
| PHILLIP NALBONE | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.